SecBot SecBot
8-K ·Filed Jun 30, 2026

NVCR

NovoCure Ltd
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago SEC0001645113-26-000056
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

The CE Mark is a material catalyst for NVCR, expanding its commercial footprint beyond the U.S. into Europe for pancreatic cancer. Monitor reimbursement decisions and initial sales in Germany over the next 1-2 quarters to gauge adoption. The strong Phase 3 data should support physician adoption and payer coverage discussions.

DirectionBullish
Confidencehigh
Horizonweeks

Optune Pax

◆ Mixed Named in this 8-K
Impact
Phase
Approved (FDA)
Time to market
Already FDA-approved and launching (February 2026). Currently commercially available in the U.S. for locally advanced pancreatic cancer.
Next catalyst
None dated

What to watchWatch the Q2 2026 earnings (late July/early August) for Optune Pax prescription and patient-start numbers to gauge the launch trajectory. The key to re-rating will be whether the commercial ramp can outpace the 2026 guidance midpoint of ~$700M total revenue. Also monitor Zai Lab's progress with China NMPA submission for a potential 2027 catalyst.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$15.15
T+0 close · Jun 30, 2026 · via day close
Latest settled
+7.26%
T+60 · $16.25
Vs SPY
+3.70%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 30 $15.15entry
  2. T+1 · 5mo ago +4.16%α +4.29% · $15.78
  3. T+5 · 4mo ago +14.32%α +13.72% · $17.32
  4. T+20 · 4mo ago +12.41%α +13.44% · $17.03
  5. T+60 · 8w ago +7.26%α +3.70% · $16.25
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NovoCure announced that its Optune Pax device received CE Mark for the treatment of locally advanced pancreatic cancer, based on Phase 3 PANOVA-3 data showing a statistically significant 2.0-month improvement in median overall survival (16.2 vs 14.2 months) and a 6.1-month delay in pain progression. This European regulatory approval follows the February 2026 FDA clearance and paves the way for commercial launch in Germany in the coming weeks, expanding the addressable market.

Key Facts

  • Optune Pax received CE Mark for locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.
  • Phase 3 PANOVA-3 trial (n=571) met primary endpoint with mOS of 16.2 months (HR=0.82, p=0.039) in ITT population.
  • mITT population showed mOS of 18.3 months (HR=0.77, p=0.023).
  • Median time to pain progression extended by 6.1 months (HR=0.74, p=0.027).
  • Device was FDA-approved in February 2026; German launch planned in coming weeks.
  • No new safety signals; device-related AEs primarily mild-to-moderate skin events.

Financial Impact

No financial figures provided; CE Mark opens European market for Optune Pax in pancreatic cancer, representing a significant revenue opportunity for NovoCure.

revenuemarket penetrationinternational sales

Risk Factors

  • Reimbursement delays or unfavorable pricing in European markets could slow revenue ramp.
  • Competition from existing pancreatic cancer therapies (e.g., chemotherapy, other devices).
  • Adoption may be gradual as clinicians need to learn the device and integrate into workflows.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
77% bullish (13 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001645113-26-000056
Document: nvcr-20260630.htm0001645113-26-000056
Document: 0001645113-26-000056-index-headers.html0001645113-26-000056
Document: 0001645113-26-000056-index.html0001645113-26-000056
Document: 0001645113-26-000056.txt0001645113-26-000056

Track record

20 reports on NVCR

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +19.75% at T+20 after the Feb 27, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $11.83 to $11.30 Now $11.30 −4.48% ▼ −4.48% −2.57% vs SPY
  2. Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
  3. Nov 9, 20267d ago 144 Neutral 2/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
  4. Nov 9, 20267d ago 8-K Bearish 6/10 Entry $12.53 to $11.81 Now $11.30 +9.82% ▲ +5.75% +5.38% vs SPY
  5. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $13.11 to $13.15 Now $11.30 −13.81% ▲ +0.31% +2.08% vs SPY
  6. Oct 1, 20266w ago 8-K Bullish 6/10 Entry $15.92 to $14.94 Now $11.30 −29.02% ▼ −6.16% −6.90% vs SPY
  7. Sep 9, 20269w ago 8-K Neutral 2/10 Entry $15.63 to $15.35 Now $11.30 −27.70% ▼ −1.79% −1.19% vs SPY
  8. Sep 1, 202610w ago 8-K Neutral 3/10 Entry $17.38 to $17.83 Now $11.30 −34.98% ▲ +2.59% +2.15% vs SPY
  9. Jul 23, 202616w ago 8-K Bullish 7/10 Entry $19.99 to $17.65 Now $11.30 −43.47% ▼ −11.71% −11.81% vs SPY
  10. Jun 30, 202619w ago 8-K Bullish 7/10 Viewing Entry $15.15 to $15.78 Now $11.30 −25.41% ▲ +4.16% +4.29% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens Wed (10h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 30, 2026